{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:22:43Z","timestamp":1788351763796,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jval.2026.03.2240","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:45:44Z","timestamp":1776354344000},"page":"1618-1625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Policy Options for New Treatments Under Uncertain External Evidence"],"prefix":"10.1016","volume":"29","author":[{"given":"Yizhi","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshen","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2026.03.2240_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2018.11.014","article-title":"Generalizability of findings from randomized controlled trials is limited in the leading general medical journals","volume":"107","author":"Malmivaara","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jval.2026.03.2240_bib2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41591-024-03352-5","article-title":"Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations","volume":"31","author":"Orcutt","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jval.2026.03.2240_bib3","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/sim.8426","article-title":"Extending inferences from a randomized trial to a new target population","volume":"39","author":"Dahabreh","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2026.03.2240_bib4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jval.2016.12.003","article-title":"Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.03.2240_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-008012","article-title":"Ethical considerations in international clinical trial site selection","volume":"7","author":"Miller","year":"2022","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.jval.2026.03.2240_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report","volume":"12","author":"Drummond","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.03.2240_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40273-023-01323-1","article-title":"Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments","volume":"42","author":"Turner","year":"2024","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jval.2026.03.2240_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40487-023-00254-3","article-title":"Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia","volume":"12","author":"Habr","year":"2024","journal-title":"Oncol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.jval.2026.03.2240_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/hec.4478","article-title":"Coverage with evidence development for medical devices in Europe: Can practice meet theory?","volume":"31","author":"Drummond","year":"2022","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2026.03.2240_bib11","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1126\/science.abk3495","article-title":"Challenges in confirming drug effectiveness after early approval","volume":"374","author":"Lynch","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jval.2026.03.2240_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069132","article-title":"Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study","volume":"13","author":"Xie","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2026.03.2240_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0272989X11399921","article-title":"Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis","volume":"31","author":"McKenna","year":"2011","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2026.03.2240_bib14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/hec.1586","article-title":"Dangerous omissions: the consequences of ignoring decision uncertainty","volume":"20","author":"Griffin","year":"2011","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2026.03.2240_bib15","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jval.2016.03.2003","article-title":"A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions","volume":"19","author":"Claxton","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.03.2240_bib16","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jval.2024.03.2196","article-title":"It Takes 2 to Tango. Setting Out the Conditions in Which Performance-Based Risk-Sharing Arrangements Work for Both Parties","volume":"27","author":"Towse","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.03.2240_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","article-title":"Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force","volume":"23","author":"Fenwick","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.03.2240_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jval.2020.01.004","article-title":"Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force","volume":"23","author":"Rothery","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.03.2240_bib19","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0272989X07312477","article-title":"The option value of delay in health technology assessment","volume":"28","author":"Eckermann","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2026.03.2240_bib20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1377\/hlthaff.2022.00119","article-title":"Accelerated Approval Of Cancer Drugs: No Economic Reward For Drug Makers That Conduct Confirmatory Trials: Study examines accelerated cancer drug trials","volume":"41","author":"Frank","year":"2022","journal-title":"Health Affairs"},{"key":"10.1016\/j.jval.2026.03.2240_bib21","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/14656566.2025.2504699","article-title":"Conditional marketing authorisation of therapeutic medicines for solid tumours in the European Union: methodological and clinical challenges","volume":"26","author":"Bellino","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jval.2026.03.2240_bib24","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1002\/sim.6728","article-title":"The power prior: theory and applications","volume":"34","author":"Ibrahim","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2026.03.2240_bib25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/hec.1781","article-title":"Accounting for between-study variation in incremental net benefit in value of information methodology","volume":"21","author":"Willan","year":"2012","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2026.03.2240_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1467-985X.2010.00673.x","article-title":"The use of propensity scores to assess the generalizability of results from randomized trials","volume":"174","author":"Stuart","year":"2001","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"10.1016\/j.jval.2026.03.2240_bib27","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"Stinnett","year":"1998","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2026.03.2240_bib28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jval.2017.11.003","article-title":"Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.03.2240_bib29","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jval.2024.02.005","article-title":"Values Beyond \"Health\" in Budget-Constrained Healthcare Systems","volume":"27","author":"Phelps","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.03.2240_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/0272989X07308751","article-title":"The value of implementation and the value of information: combined and uneven development","volume":"28","author":"Fenwick","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2026.03.2240_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.2026","article-title":"Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA","volume":"8","author":"Tibau","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jval.2026.03.2240_bib32","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1200\/JCO.24.00100","article-title":"US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma","volume":"42","author":"Cliff","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2026.03.2240_bib33","author":"Liu"},{"key":"10.1016\/j.jval.2026.03.2240_bib34","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMp1700446","article-title":"Accelerated Approval and Expensive Drugs - A Challenging Combination","volume":"376","author":"Gellad","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2026.03.2240_bib35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/1468-0009.12670","article-title":"Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval","volume":"101","author":"Neumann","year":"2023","journal-title":"Milbank Q"},{"key":"10.1016\/j.jval.2026.03.2240_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.837302","article-title":"Real World Data in Health Technology Assessment of Complex Health Technologies","volume":"13","author":"Hogervorst","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jval.2026.03.2240_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/hec.915","article-title":"Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach","volume":"14","author":"Elbasha","year":"2005","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2026.03.2240_bib38","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/hec.4932","article-title":"Value-Based Pricing for Drugs With Uncertain Clinical Benefits","volume":"34","author":"Jiao","year":"2025","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2026.03.2240_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/hec.601","article-title":"Cost-effectiveness analysis with risk aversion","volume":"10","author":"Zivin","year":"2001","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2026.03.2240_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hec.1493","article-title":"Optimal clinical trial design using value of information methods with imperfect implementation","volume":"19","author":"Willan","year":"2010","journal-title":"Health Econ"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526023831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526023831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:05:08Z","timestamp":1788350708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526023831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1098301526023831"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.03.2240","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Policy Options for New Treatments Under Uncertain External Evidence","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.03.2240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}